Advertisement
U.S. markets closed

Theraclion SA (TCLIF)

Other OTC - Other OTC Delayed Price. Currency in USD
0.59000.0000 (0.00%)
At close: 01:14PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5900
Open0.5900
BidN/A x N/A
AskN/A x N/A
Day's Range0.5900 - 0.5900
52 Week Range0.5900 - 2.2800
Volume100
Avg. Volume0
Market Cap26.083M
Beta (5Y Monthly)0.27
PE Ratio (TTM)N/A
EPS (TTM)-0.2100
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for TCLIF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • THERACLION
    Analyst Report: Baxter International Inc.Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter offers tools to help patients with acute and chronic kidney failure, which it plans to spin off in 2024. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents.
    Rating
    Fair Value
    Economic Moat
    4 months agoMorningstar
View more
  • Business Wire

    Theraclion Pursues Its Strategy and Announces Its 2023 Revenue

    MALAKOFF, France, January 29, 2024--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE) (Paris:ALTHE), an innovative company developing a scalable robotic platform for non-invasive focused ultrasound therapy (HIFU), announces today the continued execution of its value creation strategy and its turnover for 2023. One of its mainstays, sale of consumables for varicose veins, is up by a substantial 61%.

  • Business Wire

    Theraclion Delivers Its 2023 Strategic Objectives

    MALAKOFF, France, December 14, 2023--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a scalable robotic platform for non-invasive ultrasound therapy, is now taking stock of its achievements over 2023.

  • Business Wire

    Theraclion Achieves an Important Milestone on the Road to the U.S. Market: First Patients Treated With SONOVEIN® as Part of the FDA-approved Pivotal Study

    MALAKOFF, France, October 24, 2023--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE) (Paris:ALTHE), an innovative company developing a scalable robotic platform for non-invasive ultrasound therapy, announced today that it las launched the first treatments for its FDA-approved pivotal study on the treatment of varicose veins using SONOVEIN® in the United States.